The meta-analysis included 14 studies involving 130,994 patients with colorectal cancer. Pre-diagnosis statin use was linked with a 15 percent lower risk of dying early from any cause and an 18 percent lower risk of dying from cancer. Post-diagnosis statin use was linked with a 14 percent lower risk of all-cause death and a 21 percent lower risk of cancer-specific death.
“Considering that statins are low-costed and wildly-used agents worldwide, we believe our updated meta-analysis can provide new insights into optimizing adjuvant treatment of colorectal cancer,” the authors wrote.
Full bibliographic information
Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta-analysis. Cancer Med. 2019; 00: 1– 9. https://doi.org/10.1002/cam4.2151